Omada Health Announces GLP-1 Flex Care for Employers

New program pairs virtual clinical oversight, prescribing, and lifestyle coaching with employee-paid GLP-1 medications

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Omada Health announced GLP-1 Flex Care, a new employer-facing program that provides virtual clinical oversight, prescribing, and lifestyle coaching for employees using GLP-1 medications for obesity, while allowing employees to purchase the medications directly through cash-pay channels. The program aims to give employers a flexible and affordable option to support employee access to GLP-1 therapies.

Why it matters

Employer demand for GLP-1 medications is growing, but the costs of full coverage remain challenging for many. GLP-1 Flex Care allows employers to offer a structured GLP-1 option without taking on open-ended medication spend, while still providing employees with clinical oversight and lifestyle support.

The details

Through GLP-1 Flex Care, members can be evaluated for GLP-1 eligibility, have labs ordered, and receive prescriptions for FDA-approved GLP-1 medications. The program will also provide ongoing clinical oversight including titration management, support with side-effects, nutrition and activity counseling, and discontinuation support. Members will independently purchase medications through cash-pay channels while receiving Omada's virtual care and lifestyle support.

  • GLP-1 Flex Care will be available to employers beginning later in 2026.

The players

Omada Health

An American virtual-first provider of between-visit care, offering solutions for chronic conditions like obesity, diabetes, and hypertension.

Wei-Li Shao

The President of Omada Health.

Thomas Tsang, MD, MPH

The Chief Medical Officer at Omada Health.

Got photos? Submit your photos here. ›

What they’re saying

“Employers shouldn't have to choose between providing the medication and obesity care their workforce needs to be healthy and protecting their bottom line. GLP-1 Flex Care removes that tradeoff. It gives employers an affordable option they can offer today, one that keeps them in control of their spend while helping their employees get important medical oversight, prescribing, and lifestyle support.”

— Wei-Li Shao, President, Omada Health (Omada Health)

“These new pathways give more employers and members a way in, but what happens after that matters just as much. Our peer-reviewed research has shown that when GLP-1 medication was paired with Omada's wraparound care model, members stayed on their medications longer and lost more weight on average. And, more importantly, if they chose to stop, our research has shown that members maintained their weight loss on average for 12 months after discontinuing. That's the difference between a prescription and a durable outcome.”

— Thomas Tsang, MD, MPH, Chief Medical Officer, Omada Health (Omada Health)

What’s next

GLP-1 Flex Care will be available to employers beginning later in 2026. Employers interested in learning more can contact their Omada representative or visit omadahealth.com.

The takeaway

GLP-1 Flex Care provides employers with a flexible and affordable option to support employee access to GLP-1 therapies for obesity, combining virtual clinical oversight, prescribing, and lifestyle coaching with employee-paid medications. This helps employers balance the need to provide important obesity care with protecting their bottom line.